# Multifaceted roles of superoxide dismutases (SODs) in cellular homeostasis and cancer progression: Redox regulation and therapeutic implications

**Authors:** Duygu Aydemir, Nuriye Nuray Ulusu

PMC · DOI: 10.5937/jomb0-59010 · Journal of Medical Biochemistry · 2026-01-06

## TL;DR

This paper reviews how superoxide dismutases (SODs) regulate cellular balance and influence cancer progression, highlighting their roles and potential as therapeutic targets.

## Contribution

The paper provides a comprehensive overview of SODs' multifaceted roles in cancer and their therapeutic potential through SOD mimetics.

## Key findings

- SOD1 and SOD2 promote oncogenic signaling and tumor survival in cancer.
- SOD3 has context-dependent roles in tumor suppression and progression.
- Manganese-based SOD mimetics enhance cancer therapy efficacy while protecting normal tissues.

## Abstract

Superoxide dismutases (SODs) are critical metalloenzymes that regulate cellular redox homeostasis by catalysing the dismutation of superoxide radicals into hydrogen peroxide and oxygen, thereby mitigating oxidative stress. Comprising three isoforms - SOD1 (Cu/Zn-SOD), SOD2 (Mn-SOD), and SOD3 (ecSOD) - these enzymes are localised in distinct cellular compartments, including the cytosol, mitochondria, and extracellular matrix, respectively. SODs play pivotal roles in cellular signalling, metabolism, and protection against reactive oxygen species (ROS)-mediated damage. Dysregulation of SOD expression and activity is implicated in various pathological conditions, particularly cancer, where they influence tumour initiation, progression, metastasis, and therapy resistance. Elevated SOD1 and SOD2 levels often promote oncogenic signalling and tumour survival, whereas SOD3 exhibits context-dependent roles, balancing tumour suppression and progression. Additionally, SOD mimetics, notably manganese-based compounds such as Mn-porphyrins and Mn-salens, have emerged as promising therapeutic agents that selectively modulate oxidative stress in cancer cells, thereby enhancing the efficacy of chemotherapy and radiotherapy while protecting normal tissues. This review explores the multifaceted roles of SODs in cellular homeostasis, their involvement in cancer pathogenesis, and the therapeutic potential of SOD mimetics in redox-based cancer strategies.

## Linked entities

- **Genes:** SOD1 (superoxide dismutase 1) [NCBI Gene 6647], SOD2 (superoxide dismutase 2) [NCBI Gene 6648], SOD3 (superoxide dismutase 3) [NCBI Gene 6649]
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, PRKD1 (protein kinase D1) [NCBI Gene 5587] {aka CHDED, PKC-MU, PKCM, PKD, PKD1, PRKCM}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, DYRK1B (dual specificity tyrosine phosphorylation regulated kinase 1B) [NCBI Gene 9149] {aka AOMS3, MIRK}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Sod1 (superoxide dismutase 1, soluble) [NCBI Gene 20655] {aka B430204E11Rik, Cu/Zn-SOD, CuZnSOD, Ipo-1, Ipo1, SODC}, Sod3 (superoxide dismutase 3, extracellular) [NCBI Gene 20657] {aka EC-SOD}, SOD3 (superoxide dismutase 3) [NCBI Gene 6649] {aka EC-SOD}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, Sod2 (superoxide dismutase 2, mitochondrial) [NCBI Gene 20656] {aka MnSOD, Sod-2}
- **Diseases:** gastrointestinal diseases (MESH:D005767), myocardial infarction (MESH:D009203), cardiovascular damage (MESH:D002318), cytotoxic (MESH:D064420), follicular thyroid cancer (MESH:C572845), liver metastasis (MESH:D009362), thyroid, pancreatic, colon, and breast cancers (MESH:C537262), viral infection (MESH:D014777), colorectal cancer (MESH:D015179), atherosclerosis (MESH:D050197), brain disease (MESH:D001927), hypertension (MESH:D006973), tumorigenic (MESH:D002471), hepatocellular carcinoma (MESH:D006528), pulmonary hypertension (MESH:D006976), brain cancer (MESH:D001932), NPC (MESH:D000077274), glioblastoma (MESH:D005909), renal carcinoma (MESH:D002292), lymph node metastasis (MESH:D008207), breast cancer (MESH:D001943), nephropathy (MESH:D007674), inflammatory cytokines (MESH:D000080424), bacterial infection (MESH:D001424), liver failure (MESH:D017093), ovarian cancer (MESH:D010051), leukaemia (MESH:D015458), Fanconi's anaemia (MESH:D000743), peripheral neuropathy (MESH:D010523), diabetes (MESH:D003920), Cancer (MESH:D009369), fibrosarcoma (MESH:D005354), lung and oesophageal cancers (MESH:D008175), edema (MESH:D004487), thyroid or adrenal cancer (MESH:D000310), pancreatic, and colon (MESH:D010195), cardiac arrest (MESH:D006323), prostate, lung, and colon cancers (MESH:D011471), melanoma (MESH:D008545), hepatitis E (MESH:D016751), chronic shock (MESH:D012769), neurodegenerative diseases (MESH:D019636), muscle wasting (MESH:D009133), inflammation (MESH:D007249), pancreatic adenocarcinoma (MESH:D010190), mitochondrial dysfunction (MESH:D028361), skin diseases (MESH:D012871), respiratory diseases (MESH:D012140), sarcoma (MESH:D012509), neurological disorders (MESH:D009461), metabolic diseases (MESH:D008659), hypoxia (MESH:D000860), OSCC (MESH:D000077195), NSCLC (MESH:D002289), androgenetic alopecia (MESH:D000505), neurological diseases (MESH:D020271), stroke (MESH:D020521), carcinogenesis (MESH:D063646)
- **Chemicals:** Mito-TEMPO (MESH:C555916), thiols (MESH:D013438), GSSG (MESH:D019803), phenols (MESH:D010636), curcumin (MESH:D003474), Mn-porphyrins (-), superoxide (MESH:D013481), H2O2 (MESH:D006861), cisplatin (MESH:D002945), HSJ-0017 (MESH:C586813), carboplatin (MESH:D016190), alcohols (MESH:D000438), EUK-134 (MESH:C433928), calcium (MESH:D002118), ROS (MESH:D017382), Mn (MESH:D008345), GSH (MESH:D005978), peroxynitrite (MESH:D030421), Nitroxide (MESH:C039900), ATP (MESH:D000255), OH (MESH:C031356), ubiquinone (MESH:D014451), lipopolysaccharide (MESH:D008070), lipid (MESH:D008055), vincristine (MESH:D014750), paclitaxel (MESH:D017239), vinblastine (MESH:D014747), tamoxifen (MESH:D013629), salens (MESH:C011452), Ni (MESH:D009532), esters (MESH:D004952), Calmangafodipir (MESH:C060076), metal (MESH:D008670), quinones (MESH:D011809), oxygen (MESH:D010100), Zn (MESH:D015032), MnTnHex-2-PyP5+ (MESH:C583825), Cu (MESH:D003300), Mn-salens (MESH:C542902), oxaliplatin (MESH:D000077150), NO (MESH:D009569), H2O (MESH:D014867), MitoQ10 (MESH:C429015)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** alanine (Ala) to valine (Val), rs4880
- **Cell lines:** Panc1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480), SU86.86 — Homo sapiens (Human), Pancreatic adenocarcinoma, Cancer cell line (CVCL_3881)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967162/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12967162/full.md

## References

84 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967162/full.md

---
Source: https://tomesphere.com/paper/PMC12967162